Galapagos NV (GLPG) News
Filter GLPG News Items
GLPG News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GLPG News Highlights
- For GLPG, its 30 day story count is now at 4.
- Over the past 12 days, the trend for GLPG's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ASH and TW are the most mentioned tickers in articles about GLPG.
Latest GLPG News From Around the Web
Below are the latest news stories about GALAPAGOS NV that investors may wish to consider to help them evaluate GLPG as an investment opportunity.
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility of our seven-day vein-to-vein, point-of-care manufactured BCMA CAR-T candidate, GLPG5301, in adult patients with relapsed/refractory multiple myeloma (rrMM). This is Galapagos’ third oncology CAR-T program in clinical development. GLPG5301 is an autologous, second-generation |
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023. |
Best Momentum Stocks to Buy for December 13thGLPG, BBVA and TW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 13, 2023. |
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDA |
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST. The in-person event will be held at the San Diego Marriott Gaslamp Quarter in the Presidio Ballroom B/C. To register as an in-person attendee, please click here. To register as a virtual attendee, please click here. |
Retail investors invested in Galapagos NV (AMS:GLPG) copped the brunt of last week's €140m market cap declineKey Insights Galapagos' significant retail investors ownership suggests that the key decisions are influenced by... |
Galapagos NV (NASDAQ:GLPG) Q3 2023 Earnings Call TranscriptGalapagos NV (NASDAQ:GLPG) Q3 2023 Earnings Call Transcript November 5, 2023 Operator: Good day, and thank you for standing by. Welcome to the Galapagos Q3 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised […] |
Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-CareLandmark Bio, a collective endeavor bringing together leaders in industry, academia, and research hospitals to accelerate development and industrialization of next-generation genomic medicines, announced that it has signed a multi-year strategic manufacturing agreement with Galapagos NV (Euronext & NASDAQ: GLPG), an innovative biotech company with operations in Europe and the U.S. |
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financial investments of €3.8 billion at 30 September 2023Full year 2023 net Jyseleca® sales guidance of €100-€120 million and cash burn guidance of €380-€420 million reiterated Jyseleca® strategic evaluation completed: signed Letter of Intent to transfer the Jyseleca® (filgotinib) business to Alfasigma, including the European and UK Marketing Authorizations and developme |
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to AlfasigmaTransaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational medicinesAims to preserve the Jyseleca® (filgotinib) business and a significant number of positionsGalapagos plans to streamline its remaining operations and further build efficiencies Mechelen, Belgium; 30 October 2023, 21:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S.p.A. today announced th |